Marinol – a synthetic pharmaceutical that was approved by the Federal Drug Administration thirty years ago. At the time, in 1985, Marinol was the solution to legalizing medical marijuana. The issue was, however that the pharmaceutical did not help many people. There was not, and still is not, any synthesized medicine that is as efficient as the medicine derived from the entire cannabis plant. With this knowledge, many companies have been trying to get a product derived from the cannabis plant that will be extremely beneficial, rather than a replicated synthetic.
According to the Huffington Post, some fears are going to be made real in just a year:
“Look for the first naturally-derived, Big Pharma-produced cannabis product to be on the market by the first half of 2016, perhaps even sooner.
Epidiolex is a liquid formulation of pure, plant-derived cannabidiol (CBD) manufactured by the British company, G.W. Pharmaceuticals. It is currently on the FDA Fast Track and has entered its final Phase 3 study for pediatric epilepsy disorders such as Dravet’s and Lennox-Gastaut’s syndromes with results scheduled for the first quarter of 2016.
Barring an unlikely catastrophic finding, there are plenty of signs that Epidiolex will breeze through this final stage and will thus have cleared the FDA’s testing requirements. For any other drug, the remaining details would be purely administrative but Epidiolex is derived from cannabis and that puts a few more hurdles in the way before marketing can begin. There are, however, plenty of signs that government officials are literally paving the way for this new player.
Among the most significant occurred on June 24, 2015. Before a packed hearing room, the U.S. Senate Caucus on International Narcotics Control, established in 1985 to “expand international cooperation against drug abuse and narcotics trafficking” took on the decidedly domestic issue of what to do about medical cannabis. The meeting was chaired by two unlikely medical cannabis proponents, Senators Charles Grassley (R-Iowa) and Dianne Feinstein (D-CA).”
The issue is this: many people care about patients getting relief, but the pharmaceutical industry does not. The pharmaceutical industry does not care much about helping people feel better; they care more about getting people to buy medicine, and at the same time, keep them sick enough to keep coming back to buy. Because of this, people are pushing for the pharmaceutical businesses to stay out of marijuana and its medicine. Activists must get in front of this new product to ensure that it is not used corruptly.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
